Nathan Fowler

Conserved pan-cancer microenvironment subtypes predict response to immunotherapy

Alexander Bagaev, Nikita Kotlov, Krystle Nomie et al. · Cancer Cell · 2021 · 1.2K citations · Full text

Pan-cancer Microenvironment Subtypes, Cancer Immunosurveillance, Immunology +6

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

Ranjana H. Advani, Joseph J. Buggy, Jeff P. Sharman et al. · Journal of Clinical Oncology · 2012 · 1.1K citations · Full text

Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma

Wyndham H. Wilson, Ryan M. Young, Roland Schmitz et al. · Nature Medicine · 2015 · 1.1K citations · Full text

Lymphoid Neoplasia, Medicine, Immunology +5

Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas

Qing Deng, Guangchun Han, Nahum Puebla‐Osorio et al. · Nature Medicine · 2020 · 561 citations · Full text

Lymphoid Neoplasia, Radiation Oncology, Cell Therapy +10

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

Jason R. Westin, Fuliang Chu, Min Zhang et al. · The Lancet Oncology · 2013 · 528 citations · Full text

Lymphoid Neoplasia, Medicine, Immunology +10